Image by Freepik
The liver is a key organ that performs numerous vital activities in the body. It metabolizes nutrients, stores energy, controls blood sugar levels, and aids in the detoxification and removal of toxic components and medicines. Liver cancer is one of the most fatal types of cancer in the globe. Obesity, heavy alcohol intake, and hepatitis C infection are all risk factors for liver cancer. Early detection and proper therapy techniques are critical for improving liver cancer therapies and killing tumor cell.
Cancer is classified as a metabolic disorder
Scientists have made significant progress in comprehending the various aspects of cancer during the last decade. It has long been thought to be a problem with cell growth. There is, however, mounting evidence that cancer is a metabolic illness. Cancer develops when cells rearrange their metabolism to facilitate uncontrolled cell multiplication. How can cells alter their metabolism, and how does this alteration result in tumorigenicity? Researchers from the Biozentrum, University of Basel, lead by Professor Michael N. Hall, have uncovered a major driver of metabolic rewiring in liver cancer cells in a recent study published in “Cell.”
Arginine accumulation in liver carcinoma
When healthy liver cells transform into cancer cells, their behavior progressively changes. They alter their metabolism to expand as quickly as possible, consuming significantly more glucose than normal cells and increasing food intake.
“We investigated liver tumor samples from mice and patients and found elevated levels of arginine, although cancer cells produce less or none of this amino acid. The tumor cells accumulate high levels of arginine by increasing its uptake and suppressing its consumption,” says lead author Dr. Dirk Mossmann. “Furthermore, we found that the high levels of arginine are necessary for tumor development, independently of the amino acid’s role in protein synthesis. This then begged the question, how does arginine lead to tumorigenicity?”
Arginine’s function in tumor growth
At high quantities, arginine binds to a particular factor, which causes metabolic reprogramming and promotes tumor growth by regulating metabolic gene expression. As a result, tumor cell return to an undifferentiated embryonic cell state and can divide indefinitely. Interestingly, boosting arginine absorption benefits tumor cells in another way. “Our immune cells rely on arginine to function properly,” Mossmann says. “Therefore, depleting arginine in the tumor environment helps the tumor cell escape the immune system.”
Implications for liver cancer diagnosis and treatment
What does this signify for cancer treatment? Rather of decreasing arginine, the scientists recommend targeting a specific arginine-binding component. “When treating liver tumors with the anticancer drug indisulam, we induce the degradation of this factor and thus prevent metabolic reprogramming” , according to Mossmann. Via this route, one can avoid unwanted side effects of reducing overall arginine levels, like harming immune cells that need arginine to work properly.” Furthermore, metabolic changes such as elevated arginine levels may act as biomarkers for early detection of cancer, which is critical for successful cancer treatment and patient survival.
More Information: Arginine reprograms metabolism in liver cancer via RBM39, Cell Press
more recommended stories
Air Pollution Hurts Brain Health in Just 4 HoursAir Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences DivisionThe TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Leave a Comment